Extracellular Vesicle Therapy for Type 1 Diabetes

Soltani, S.; Mansouri, K.; Emami Aleagha, M.S.; Moasefi, N.; Yavari, N.; Shakouri, S.K.; Notararigo, Sara; Shojaeian, A.; Pociot, F.; Yarani, R.

doi:10.3389/fimmu.2022.865782

Soltani, S.; Mansouri, K.; Emami Aleagha, M.S.; Moasefi, N.; Yavari, N.; Shakouri, S.K.; Notararigo, Sara; Shojaeian, A.; Pociot, F.; Yarani, R.

Estadísticas

Ver Estadísticas de uso

Identificadores

URI: http://hdl.handle.net/20.500.11940/20830

DOI: 10.3389/fimmu.2022.865782

ISSN: 1664-3224

Registro completo

Servicios

Visualización o descarga de ficheros

Soltani S, Mansouri K, Emami Aleagha MS, Moasefi N, Yavari N, Shakouri SK, et al. Extracellular Vesicle Therapy for Type 1 Diabetes. Frontiers in Immunology. Frontiers Media S.A.; 2022;13. (1.292Mb)

Fecha de publicación

2022

Título de revista

Frontiers in Immunology

Tipo de contenido

Review

Resumen

Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing ?-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional

Repositorio digital RUNA